COMMUNIQUÉS West-GlobeNewswire

Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rollout Demand for AGAMREE [...]
Communiqué de presse : La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1
23/09/2025
La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1 Admission obtenue pour la thérapie génique AAV unique [...]
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23/09/2025
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expression Myotonic [...]
Addex Appoints Bank of New York Mellon as Depositary Bank
23/09/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 BST. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
23/09/2025
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform
22/09/2025
AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for [...]
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
22/09/2025
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]
J-Star Holding Names Sam Van as Chief Executive Officer
22/09/2025
TAICHUNG CITY, Taiwan, Sept. 22, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
22/09/2025
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 [...]
GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société
22/09/2025
Trésorerie et équivalents de trésorerie s’élevant à 107,5 millions d’euros au 30 juin 2025 n’incluant pas le paiement d’étape de 26,5 millions d’euros facturé en mai 2025 (reçu en juillet 2025) à la suite de l' [...]
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
22/09/2025
Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) [...]
MBX Biosciences Announces Proposed Public Offering
22/09/2025
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
BetaGlue Therapeutics annonce la nomination d’Alexis Peyroles au poste de directeur général
22/09/2025
MILAN, 22 sept. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une entreprise d’oncologie en phase clinique développant une plateforme innovante de radiothérapie pour le traitement [...]
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
22/09/2025
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Fortrea Appoints William Sharbaugh to Board of Directors
22/09/2025
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company’s Board [...]
AMN Healthcare Announces Pricing of Senior Notes Offering
22/09/2025
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of $400.0 [...]
MEDIA ADVISORY - Protests Against Ford Government’s Expanding Hospital Privatization Plans
22/09/2025
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- “The Ford government is privatizing our public hospitals in a move that is costing patients thousands of dollars and taking away from our local public hospital services. [...]
The Sentinel Introduces Transformative Approach to Healing in British Columbia, Setting a New Standard in Integrative Care
22/09/2025
KASLO, BC, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The Sentinel , a leading wellness centre, today announced a major initiative advancing the integration of traditional healing practices with contemporary therapeutic [...]

Pages